These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 10431581

  • 1. [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT].
    Sumiyoshi Y, Hashine K, Kuwahara M, Aki M, Yamamoto A, Akazawa S, Takenaka A.
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1153-8. PubMed ID: 10431581
    [Abstract] [Full Text] [Related]

  • 2. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K, Lehnert M, Stettner H, Hubmer G.
    Eur Urol; 1997 Jul; 32 Suppl 3():81-5. PubMed ID: 9267791
    [Abstract] [Full Text] [Related]

  • 3. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
    Ito T, Aizawa T, Yamamoto S, Ohkubo Y, Tsujino S, Miki M.
    Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
    [Abstract] [Full Text] [Related]

  • 4. [Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group].
    Uchida K, Takeshima H, Kikuchi K, Shimazui T, Miyanaga N, Kawai K, Akaza H, Tsuchiya A, Noguchi R, Hattori K, Manabe F, Matsuki K, Suzuki R, Ishikawa S, Kondo F, Kobayashi T, Koiso K.
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1179-87. PubMed ID: 9679581
    [Abstract] [Full Text] [Related]

  • 5. [Clinical evaluation of chemohormonal therapy as an initial treatment for stage D2 prostatic cancer--effect of UFT administration combined with hormonal therapy].
    Honda M, Takasaki E, Suzuki T, Maeda S, Imai T, Hosoya Y, Chen JA.
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):105-9. PubMed ID: 7826063
    [Abstract] [Full Text] [Related]

  • 6. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW.
    BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N, Arima K, Sugimura Y.
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N, Figg WD, Brawley OW, Bergan R, Cooper MR, Senderowicz A, Headlee D, Steinberg SM, Sutherland M, Patronas N, Sausville E, Linehan WM, Reed E, Sartor O.
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [Abstract] [Full Text] [Related]

  • 12. [Total androgen blockade for prostate cancer].
    Kagebayashi Y, Ozono S, Takashima K, Yoshikawa M, Hayashi Y, Kaneko Y, Maruyama Y, Hirao Y, Okajima E.
    Hinyokika Kiyo; 1997 Mar; 43(3):197-201. PubMed ID: 9127754
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM, Rose AL, Higano C.
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [Abstract] [Full Text] [Related]

  • 15. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
    Bogdanos J, Karamanolakis D, Milathianakis C, Repousis P, Tsintavis A, Koutsilieris M.
    Anticancer Res; 2003 Nov; 23(2C):1757-62. PubMed ID: 12820454
    [Abstract] [Full Text] [Related]

  • 16. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S, Canadian Uro-Oncology Group.
    J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [Abstract] [Full Text] [Related]

  • 17. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

  • 18. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [Abstract] [Full Text] [Related]

  • 19. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ, Brandt D, Schour L, Hill DR.
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.